General
Preferred name
TAZAROTENE
Synonyms
AGN 190168 ()
Tazorac ()
Zorac ()
Tazarotene, AGN 190168 ()
PMID27336223-Compound-10 ()
AGN190168 ()
Arazlo ()
Fabior ()
AGN-190168 ()
Avage ()
Idp-123 ()
P&D ID
PD009714
CAS
118292-40-3
Tags
prodrug
natural product
drug
available
Approved by
FDA
First approval
1997
Drug Status
investigational
approved
Drug indication
Keratolytic
Psoriasis vulgaris
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Tazarotene is a vitamin A-like retinoid that binds all isoforms of the retinoic acid receptor, but may show selectivity for the β, and γ isoforms acting via which may result in altered gene expression that provides the beneficial effects on skin condition. Tazarotene is essentailly a prodrug, with tazarotenic acid (PubChem CID 147525) being the active metabolite.
(GtoPdb)
PHARMACODYNAMICS
Following topical application, tazarotene undergoes esterase hydrolysis to form its active metabolite, tazarotenic acid. When treating acne tazarotene may be taken in conjunction with an oral antibiotic. Tazarotene has been shown in peer-reviewed double blinded studies to reduce: mottling and hyperpigmentation, sallowness, fine wrinkling and coarse wrinkling in sun damaged skin. Histological studies have shown that long term (greater than 1 year) use of Tazarotene is associated with a significant reduction in atypical melanocytes and keratocytes - cells considered to be precursors of skin cancer. Some studies have shown long term use of Tazarotene to be associated with increased collagen production and better organization of skin collagen bundles.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
26
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
EUbOPEN Chemogenomics Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
44
Molecular Weight
351.13
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
4.43
TPSA
39.19
Fraction CSP3
0.33
Chiral centers
0.0
Largest ring
6.0
QED
0.59
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Metabolism
Autophagy
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Target
RAR
RARA, RARB, RARG, RXRB
RAR/RXR
Retinoid Receptor
Member status
member
MOA
Retinoid RARgamma Agonists
Ornithine Decarboxylase Inhibitors
Retinoid RARbeta Agonists
Retinoid Receptor agonist
Indication
cosmetic, sunscreen lotion
Therapeutic Class
Dermatologic Agents
Source data
